Q&A

Highly Potent APIs Are Becoming More Potent And Complex

Source: Evonik Corporation
Evonik

Dr. Andreas Meudt is the global head of Exclusive Synthesis for Evonik, one of the world’s top three CMOs for APIs and the largest for highly potent APIs (HPAPIs). In this interview, Dr. Meudt shares his thoughts on key growth trends for HPAPIs, and why more pharma companies are outsourcing their production to contract specialists.

access the Q&A!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)

Evonik Corporation